Amedisys (AMED)
(Delayed Data from NSDQ)
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Amedisys (AMED) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$100.88 | $101.00 | $100.00 | 5.04% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Amedisys comes to $100.88. The forecasts range from a low of $100.00 to a high of $101.00. The average price target represents an increase of 5.04% from the last closing price of $96.04.
Analyst Price Targets (8 )
Broker Rating
Amedisys currently has an average brokerage recommendation (ABR) of 2.90 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 2.90 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, one is Buy, representing 10% of all recommendations. A month ago, Buy represented 10%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 1 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 9 | 9 | 9 | 10 | 9 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.90 | 2.90 | 2.90 | 2.91 | 2.73 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/2/2024 | SVB Securities | Whit Mayo | Hold | Hold |
8/1/2024 | Stephens | Scott Fidel | Hold | Hold |
7/25/2024 | Cantor Fitzgerald & Co | Sarah James | Hold | Hold |
7/11/2024 | Cowen & Co. | Ryan Langston | Not Available | Hold |
7/1/2024 | William Blair | Matt Larew | Strong Buy | Hold |
4/25/2024 | Truist Securities | David S Macdonald | Hold | Hold |
3/26/2024 | Raymond James | John W Ransom | Hold | Hold |
3/25/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.90 |
ABR (Last week) | 2.90 |
# of Recs in ABR | 10 |
Average Target Price | $100.88 |
LT Growth Rate | 11.00% |
Industry | Medical - Outpatient and Home Healthcare |
Industry Rank by ABR | 45 of 252 |
Current Quarter EPS Est: | 1.14 |
AMED FAQs
Amedisys, Inc. (AMED) currently has an average brokerage recommendation (ABR) of 2.90 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms.
The average price target for Amedisys, Inc. (AMED) is $100.88. The current on short-term price targets is based on 8 reports.
The forecasts for Amedisys, Inc. (AMED) range from a low of $100 to a high of $101. The average price target represents a increase of $4.95 from the last closing price of $96.12.
The current UPSIDE for Amedisys, Inc. (AMED) is 4.95%
Based on short-term price targets offered by eight analysts, the average price target for Amedisys comes to $100.88. The forecasts range from a low of $100.00 to a high of $101.00. The average price target represents an increase of 5.04% from the last closing price of $96.04.